| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.2 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |